Mafenide (Sulfamylon) Cream, Solution - Uses, Side effects, Warnings

Mafenide (Sulfamylon) is a broad-spectrum antibiotic with activity against gram-positive and gram-negative bacteria including Pseudomonas aeruginosa. It is used as a topical solution or cream in patients with second or third-degree burns.

Mafenide (Sulfamylon) Uses:

  • Burn treatment:

    • It is used as an adjunctive treatment in patients with second-degree or third-degree burns as a topical antimicrobial cream to control bacterial infection.
    • It is used over meshed autografts on excised burn wounds (powder for solution) under moist dressings.

Mafenide (Sulfamylon) Dose in Adults:

Mafenide (Sulfamylon) Dose in the treatment of Burn: Topical:

  • Cream:
    • Apply the cream with a sterile-gloved hand once or twice a day.
    • Apply as a thin layer over the burned area.
    • Cover the burned area at all times until healing or the burned site is ready for grafting.
  • Powder for solution:
    • Cover the graft area with an 8-ply burn dressing soaked in the solution.
    • The dressings should be kept wet using an irrigation tubing or a syringe every four hours as necessary.
    • The treatment should be continued until revascularization of the autograft occurs and healing is progressing.
    • The dressing may be kept in place not exceeding five days.

Mafenide (Sulfamylon) Dose in the treatment of Burns: Topical:

  • Infants, Children, and Adolescents:

    • Cream:
      • Apply the cream with a sterile-gloved hand once or twice a day.
      • Apply as a thin layer that covers the burned surface at all times.
  • Infants ≥3 months, Children, and Adolescents:

    • Solution (5%):
      • The burned area should be covered with a layer of meshed gauze piece.
      • The graft area should be covered with an 8-ply burn dressing soaked in the solution.
      • The dressing should be kept wet using an irrigation tubing or a wet syringe every four hours or as necessary.
      • The dressing may be kept in place not exceeding five days and should be secured and wrapped with bolster dressing as appropriate.

Pregnancy Risk Category: C

  • Animal reproduction studies did not show any adverse reactions when the drug was given orally.
  • The cream should not be used by women under the age of 20 years.

Use Mafenide while breastfeeding

  • It is unknown if the drug will be excreted into breastmilk.
  • The manufacturer suggests that infants not be breastfed due to the potential for serious adverse drug reactions.

Mafenide (Sulfamylon) Dose in Kidney Disease:

  • In the manufacturer's labeling, there are no contraindications mentioned.
  • It should, however, be used with caution in patients with renal failure because of drug accumulation and metabolic acidosis.

Mafenide (Sulfamylon) Dose in Liver disease:

In the manufacturer's labeling, there are no contraindications mentioned.


Side effects of Mafenide (Sulfamylon):

  • Cardiovascular:

    • Edema
    • Facial Edema
  • Dermatologic:

    • Erythema
    • Maceration
    • Pruritus
    • Rash
    • Urticaria
  • Endocrine & Metabolic:

    • Hyperchloremia
    • Metabolic Acidosis
  • Gastrointestinal:

    • Diarrhea (Following Accidental Ingestion)
  • Hematologic:

    • Bleeding
    • Bone Marrow Suppression
    • DIC
    • Eosinophilia
    • Hemolytic Anemia
    • Porphyria
  • Local:

    • Blisters
    • Burning Sensation,
    • Excoriation
    • Pain
  • Respiratory:

    • Dyspnea
    • Hyperventilation
    • Pco Decreased
    • Tachypnea
  • Miscellaneous:

    • Hypersensitivity

Contraindications to Mafenide (Sulfamylon):

Allergy to mafenide, or any component of this formulation

Warnings and precautions

  • Acid-base imbalance

    • The inhibitory effect of the drug upon the enzyme carbonic anihydrase may cause metabolic acidosis.
    • Patients with impaired renal function may experience metabolic acidosis more often.
    • Metabolic acidosis symptoms are subtle and may manifest only as an increase of the respiratory rate (due compensatory hyperventilation).
    • Patients with severe burns and patients with renal dysfunction or pulmonary dysfunction should be closely monitored for venous or arterial PH.
  • Allergy to sulfonamide

    • Patients who are allergic to sulfonamides or sulfonylureas, thiazide diuretics, thiazide diuretics or loop diuretics (except for ethacrynic acids), should not use it.
    • Patients who have had an allergic reaction in the past should not use the drug.
  • Superinfection

    • Long-term use of the drug can lead to superinfection, including serious bacterial or fungal infections.
    • The risk of antibiotic-associated pseudomembranous colitis may occur as later as two months after the last dose of antibiotics.
  • G6PD deficiency:

    • G6PD deficiency can lead to acute hemolytic crises and DIC (disseminated intravascular coagulation), which may prove fatal.
    • These patients should use it with caution.
  • Renal impairment

    • Patients with acute renal impairment should not be given the drug.
    • Due to drug accumulation and carbonic anhydrase inhibitor, the risk of metabolic acidosis could increase.

Mafenide: Drug Interaction

Risk Factor C (Monitor therapy)

BCG Vaccine (Immunization)

Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization).

Dapsone (Topical)

May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.

Local Anesthetics

Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.

Nitric Oxide

May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.

Prilocaine

Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia. Avoid lidocaine/prilocaine in infants receiving such agents.

Sodium Nitrite

Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia.

Risk Factor D (Consider therapy modification)

Sodium Picosulfate

Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.

Risk Factor X (Avoid combination)

BCG (Intravesical)

Antibiotics may diminish the therapeutic effect of BCG (Intravesical).

 

Monitoring parameters:

  • Acid base balance
  • Monitor for superimposed infections and healing

How to administer Topical Mafenide (Sulfamylon)?

Cream:

  • It is intended for topical (external) use only. The burn area should be covered with the medicated cream at all times.
  • Dressings are not required but a thin layer of dressings may be used.
  • The cream should be applied using a sterile gloved hand to a clean area that has been debrided. A thin layer of the drug should be applied.
  • If the possibility of infection persists, treatment must not be discontinued. To help in the debridement of the wound, the patient should be bathed daily.

Powder for solution:

  • It is intended for external use only.
  • The graft area should be covered with one layer of fine mesh gauze.
  • An 8-ply burn dressing should be soaked with the solution until leaking is noticeable and the graft area should be covered with it.
  • The dressings should be kept wet using a syringe or irrigation tubing or by moistening dressing.
  • Irrigation tubing should be placed over the burn dressing in contact with the wound;
  • An additional 8-ply dressing should be used to cover the area.
  • The irrigation dressing should be secured with bolster dressing and wrapped as appropriate.

Mechanism of action of Mafenide (Sulfamylon):

  • It is a sulfonamide anti-biotic that competes against para-aminobenzoic acids and interferes with bacterial folic acid synthesis.
  • It is effective against both gram positive and gram negative organisms, including pseudomonas Aeruginosa as well as anaerobic and anaerobic diseases.

Absorption:

  • It absorbs quickly from the burnt surface and diffuses through devascularized areas.

Metabolism:

  • It is metabolized to para-carboxybenzene sulfonamide.
  • Mafenide and metabolite are carbonic anhydrase inhibitors

The time to peak serum concentration:

  • Cream 11%: 2 to 4 hours
  • Burn tissue:
    • Cream 11%: 2 hours,
    • Solution 5%: 4 hours

Excretion:

  • Urine (as metabolites)

International Brands of Mafenide:

  • Sulfamylon
  • Homonal
  • Mafatate
  • Mefede
  • Sulfamylon
  • Sulfomyl

Mafenide Brands Names in Pakistan:

No Brands Available in Pakistan.

Comments

NO Comments Found